Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (5) , e909-e912
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 23 references indexed in Scilit:
- Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaJAMA Oncology, 2018
- Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case seriesGynecologic Oncology Reports, 2018
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 2018
- Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic ProfileEuropean Urology, 2018
- Tumor Mutational Burden and Response Rate to PD-1 InhibitionNew England Journal of Medicine, 2017
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validationThe Lancet Oncology, 2013
- The role of BRCA1 in DNA damage responseProtein & Cell, 2010